Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255366 | 1.00 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 | |
| SCHEMBL14196497 | 0.85 | GAA (0.54) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 | |
| SCHEMBL2336250 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 | |
| SCHEMBL2336247 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 | |
| SCHEMBL12245583 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 | |
| SCHEMBL2332699 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 | |
| SCHEMBL12245585 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 | |
| SCHEMBL2332697 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 | |
| SCHEMBL16683309 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 | |
| SCHEMBL22366970 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AG6PC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268933-B2 | Polymers functionalized with polyimine compounds | BRIDGESTONE CORPORATION (JP) | 2012-09-18 | — | — | US | claimed |
| US-20090171035-A1 | POLYMERS FUNCTIONALIZED WITH POLYIMINE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2009-07-02 | — | — | US | claimed |
| US-20240182421-A1 | SYNTHESIS OF ENDOCHIN-LIKE QUINOLONES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4308109-A1 | SYNTHESIS OF ENDOCHIN-LIKE QUINOLONES | Oregon Health & Science University (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197979-A1 | SYNTHESIS OF ENDOCHIN-LIKE QUINOLONES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-09-22 | — | — | WO | disclosed |
| US-8853352-B2 | Functionalized polymer and method for making | BRIDGESTONE CORPORATION (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8268933-B2 | Polymers functionalized with polyimine compounds | BRIDGESTONE CORPORATION (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090171035-A1 | POLYMERS FUNCTIONALIZED WITH POLYIMINE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20080154020-A1 | introducing imine compounds into carbanionic (living) polymers, that can interact with particle filler such as carbon black and silica | BRIDGESTONE CORPORATION (JP) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182421-A1 | SYNTHESIS OF ENDOCHIN-LIKE QUINOLONES | ENGASE, ESYT2, VPS4B | SMN1; SMN2 4828/4885NPC1 1135/4885RAB9A 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.